Neumora Therapeutics (NMRA) Corporate presentation summary

Mission and leadership

• Focused on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.

• Led by an experienced team with backgrounds in major pharmaceutical and biotech companies.

Market focus and unmet needs

• Targeting large markets with significant unmet needs, including metabolic, neurodegenerative, and neuropsychiatric diseases.

• Aims to provide improved tolerability, novel mechanisms of action, and easier-to-maintain treatments.

Pipeline and clinical programs

• Advancing three core franchises: metabolic disease (NMRA-215), neurodegenerative disease (NMRA-511, NMRA-GCASE, NMRA-CK15), and neuropsychiatric disease (Navacaprant, NMRA-898, NMRA-861).

• Multiple programs in preclinical to Phase 3 stages, with key milestones expected in 2026.